Elotuzumab – Anti-CS1 Antibody for Multiple Myeloma
Key Data:
Drug (Brand / Generic)
Elotuzumab (HuLuc63)
Company / Licensee
PDL Biopharma / Bristol-Myers Squibb
Therapy Class
Anti-neoplastic agent
Product Description
Anti-CS1 humanised monoclonal antibody
Current Indication
Multiple myeloma
Market Sector
Oncology
Development Status
Phase I/II
